Northwest Biotherapeutics, Inc.
NWBO
$0.17
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 40.04% | 84.13% | 104.92% | -38.48% | 13.94% |
| Total Depreciation and Amortization | 64.80% | 70.08% | 59.88% | -0.19% | 0.19% |
| Total Amortization of Deferred Charges | -76.19% | -17.07% | -28.44% | -24.86% | 6.92% |
| Total Other Non-Cash Items | -243.00% | -419.65% | -461.94% | 49.29% | 1,752.98% |
| Change in Net Operating Assets | 3.59% | -129.66% | -144.83% | -30.37% | 484.75% |
| Cash from Operations | -7.19% | -32.82% | 26.84% | -68.75% | 58.71% |
| Capital Expenditure | 34.87% | -38.71% | -1,060.26% | -14.77% | 41.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 34.87% | -38.71% | -1,060.26% | -191.48% | 41.65% |
| Total Debt Issued | 49.33% | 3.74% | -4.36% | 43.07% | -46.93% |
| Total Debt Repaid | -627.72% | 17.63% | 100.00% | 40.27% | 26.10% |
| Issuance of Common Stock | -98.39% | -43.46% | -52.30% | -31.90% | 138.06% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -40.78% | -21.51% | -14.77% | -0.53% | -27.37% |
| Foreign Exchange rate Adjustments | 69.48% | 234.43% | -84.21% | 198.07% | -22,952.94% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -177.49% | -307.62% | -98.95% | 320.69% | 281.39% |